Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi/GSK’s Vidprevtyn Is Fifth COVID-19 Vaccine Candidate Under Rolling Review at EMA

Executive Summary

Sanofi and GSK are way behind in the COVID-19 vaccine race and the start of a rolling review of Vizprevtyn at the European Medicines Agency is an important step.

You may also be interested in...



Eye On Delta, Sanofi/GSK To Begin India Trials Of COVID-19 Vaccine

Sanofi and GSK, which are in the middle of Phase III global trials for their COVID-19 vaccine candidate, plan to test the contender against all variants of concern including the highly contagious Delta variant, Scrip has learned. Meanwhile, Pfizer/BioNTech is looking at a booster to combat lower efficacy/effectiveness against this variant. 

Walmsley Under Pressure Over GSK’s Strategy

GSK’s share price is down by 15% since Walmsley took over as CEO, but major investors are said to be resisting calls for a radical re-think in its strategy.

EU Accelerated Assessment Tracker

Marinus’s ganaxolone has lost its accelerated assessment status mid-review at the European Medicines Agency while Roche’s glofitamab will be fast-tracked once a filing has been made.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS144688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel